Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with PEG-IFN α-2a and Tenofovir Disoproxil Fumarate

Trial Profile

A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with PEG-IFN α-2a and Tenofovir Disoproxil Fumarate

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2018

At a glance

  • Drugs ARB 1467 (Primary) ; Peginterferon alfa-2a (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Arbutus Biopharma
  • Most Recent Events

    • 07 Nov 2018 According to an Arbutus Biopharma media release, the company does not plan to advance ARB-1467 program beyond this trial.Also, the company intend to present results from this trial in a future scientific meeting.
    • 28 Oct 2018 This trial has been Discontinued in Spain.
    • 09 Oct 2018 According to an Arbutus Biopharma media release, six HBV patients have enrolled and been treated till date in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top